Chronic inflammatory muscle diseases and risk of coronary artery disease

Current Atherosclerosis Reports

Volumn 15, Issue 3, 2013, Pages

  Gundogdu, Betul M ^a   Cilingiroglu, Mehmet ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Chronic inflammatory muscle diseases; Coronary artery disease; Endothelial dysfunction

Indexed keywords

C REACTIVE PROTEIN;

ATHEROGENESIS; AUTOIMMUNE DISEASE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CHRONIC INFLAMMATION; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE COURSE; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; HUMAN; IMMUNOPATHOGENESIS; INFLAMMATORY CELL; MYOSITIS; NONHUMAN; PERIPHERAL VASCULAR DISEASE; REVIEW; RISK REDUCTION; VASCULAR ENDOTHELIUM; HEALTH; INCIDENCE; PATHOPHYSIOLOGY; RISK FACTOR; VASCULAR RESISTANCE;

CORONARY ARTERY DISEASE; DISEASE PROGRESSION; ENDOTHELIUM, VASCULAR; HUMANS; INCIDENCE; MYOSITIS; RISK FACTORS; VASCULAR RESISTANCE; WORLD HEALTH;

MLCS; MLOWN;

EID: 84872452205     PISSN: 15233804     EISSN: 15346242     Source Type: Journal    
DOI: 10.1007/s11883-012-0308-2     Document Type: Review

References (35)

1. Eyre H, Kahn R, Robertson RM. Preventing cancer, cardiovascular disease, and diabetes: a common agenda for the American Cancer Society, the American Diabetes Association, and the American Heart Association. CA Cancer J Clin. 2004;54:190-207. (Pubitemid 39136580)
2. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352:1685-95.
3. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTER- HEART study): case-control study. Lancet. 2004;364:937-52. (Pubitemid 39208455)
4. Libby P. Inflammation and cardiovascular disease mechanisms. Am J Clin Nutr. 2006;83:456S-60S. This article is of major importance because it reviews the mechanism of inflammatory mediators in CAD.
5. Libby P. Role of inflammation in atherosclerosis associated with rheumatoid arthritis. Am J Med. 2008;121:S21-31. This article is of importance because it evaluates the potential role of chronic inflammatory diseases in the cause of CAD.
6. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated Creactive protein. N Engl J Med. 2008;359:2195-207.
7. Trion A, de Maat MP, Jukema JW, et al. No effect of C-reactive protein on early atherosclerosis development in apolipoprotein E*3-leiden/human C-reactive protein transgenic mice. Arterioscler Thromb Vasc Biol. 2005;25:1635-40. (Pubitemid 41098933)
8. Tennent GA, Hutchinson WL, Kahan MC, et al. Transgenic human CRP is not pro-atherogenic, pro-atherothrombotic or proinflammatory in apoE-/- mice. Atherosclerosis. 2008;196:248-55.
9. Ortiz MA, Campana GL, Woods JR, et al. Continuously-infused human C-reactive protein is neither proatherosclerotic nor proinflammatory in apolipoprotein E-deficient mice. Exp Biol Med (Maywood). 2009;234:624-31.
10. Torzewski M, Reifenberg K, Cheng F, et al. No effect of C-reactive protein on early atherosclerosis in LDLR-/- human C-reactive protein transgenic mice. Thromb Haemost. 2008;99:196-201.
11. Zacho J, Tybjaerg-Hansen A, Jensen JS, et al. Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med. 2008;359:1897-908.
12. Zacho J, Tybjaerg-Hansen A, Nordestgaard BG. C-reactive protein, genetically elevated levels and risk of ischemic heart and cerebrovascular disease. Scand J Clin Lab Invest. 2009;69:442-6.
13. Dalakas MC. Inflammatory muscle diseases; a critical review on pathogenesis and therapies. Curr Opin Pharmacol. 2010;10:346-52.
14. Schmidt J, Dalakas MC. Pathomechanisms of inflammatory myopathies: recent advances and implications for diagnosis and therapies. Exp Opin. 2010;4:241-50.
15. Dalakas MC. Polymyositis, dermatomyositis, and inclusion-body myositis. N Engl J Med. 1991;325:1487-98.
16. Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet. 2003;362:971-82. (Pubitemid 37159295)
17. Engel AG, Hohlfeld R, Banker BQ. The polymyositis and dermatomyositis syndrome. In: Engel AG, editor. Myology. New York: McGraw-Hill; 2008. p. 1335-83.
18. Tisseverasinghe A, Bernatsky S, Pineau CA. Arterial events in persons with dermatomyositis and polymyositis. J Rheumatol. 2009;36:1943-6. This article is of major importance because it defines a possible association between chronic inflammatory muscle diseases and CAD.
19. Szmitko PE, Wang CH, Weisel RD, et al. New markers of inflammation and endothelial cell activation: part I. Circulation. 2003;108:1917-23. (Pubitemid 37296533)
20. Verma S, Anderson TJ. Fundamentals of endothelial function for the clinical cardiologist. Circulation. 2002;105:546 -9.
21. Verma S, Buchanan MR, Anderson TJ. Endothelial function testing as a biomarker of vascular disease. Circulation. 2003;108:2054-9. (Pubitemid 37337577)
22. Verma S, Szmitko PE, Anderson TJ. Endothelial function: ready for prime time? Can J Cardiol. 2004;20:1335-9. (Pubitemid 39654368)
23. Ridker PM, Rifai N, Pfeffer MA, et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation. 1998;98:839-44. (Pubitemid 28397432)
24. Anderson JL. Lipoprotein-associated phospholipase A2: an independent predictor of coronary artery disease events in primary and secondary prevention. Am J Cardiol. 2008;101:23F-33F.
25. Liuzzo G. Atherosclerosis: an inflammatory disease. Rays. 2001;26:221-30.
26. Heeschen C, Dimmeler S, Hamm CW, et al. Serum level of the anti inflammatory cytokine interleukin-10 is an important prognostic determinant in patients with acute coronary syndromes. Circulation. 2003;107:2109-14. (Pubitemid 36532192)
27. Pearson TA, Blair SN, Daniels SR, et al. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: Consensus Panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation. 2002;106:388-91. (Pubitemid 34778969)
28. Zebrack JS, Anderson JL, Maycock CA, et al. Usefulness of high-sensitivity C-reactive protein in predicting long-term risk of death or acute myocardial infarction in patients with unstable or stable angina pectoris or acute myocardial infarction. Am J Cardiol. 2002;89:145-9. (Pubitemid 34132900)
29. Zebrack JS, Muhlestein JB, Horne BD, Anderson JL. C-reactive protein and angiographic coronary artery disease: independent and additive predictors of risk in subjects with angina. J Am Coll Cardiol. 2002;39:632-7. (Pubitemid 34158159)
30. Heeschen C, Hamm CW, Bruemmer J, Simoons ML. Predictive value of C-reactive protein and troponin T in patients with unstable angina: a comparative analysis. CAPTURE Investigators. Chimeric c7E3 Anti-Platelet Therapy in Unstable angina REfractory to standard treatment trial. J Am Coll Cardiol. 2000;35:1535-42.
31. Liuzzo G, Biasucci LM, Gallimore JR, et al. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med. 1994;331:417-24. (Pubitemid 24247397)
32. Toss H, Lindahl B, Siegbahn A, Wallentin L. Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease. FRISC Study Group. Fragmin during instability in coronary artery disease. Circulation. 1997;96:4204-10. (Pubitemid 28007445)
33. Buckley DI, Fu R, Freeman M, Rogers K, Helfand M. C-reactive protein as a risk factor for coronary heart disease: a systematic review and meta- analyses for the U.S. Preventive Services Task Force. Ann Intern Med. 2009;151:483-95.
34. Dalakas MC. Adaptive immunity and atherosclerosis. Pathophysiology of inflammatory and autoimmune myopathies. Presse Med. 2011;40(4 Pt 2):e237-47.
35. Andersson J, Libby P, Hansson GK. Adaptive immunity and atherosclerosis. Clin Immunol. 2010;134(1):33-46.